To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
Tecan and Enigma Sign Global Manufacturing and Supply Agreement for Molecular Diagnostics Instruments
Read time: Less than a minute
The Tecan Group
and
Enigma Diagnostics Limited
announced the signing of a manufacturing and supply agreement for Enigma’s ML instruments.
Under the agreement, Tecan will industrialize and deliver commercially manufactured ML instruments for Enigma’s global market supplies for an initial five-year contract and will also manage the ML instrument’s supply chain. The first ML demonstration instruments have been delivered for Enigma’s GlaxoSmithKline delivery commitments for point-of-care molecular diagnostic influenza tests.
The launch of Enigma ML and supply of commercial series systems for its initial use to identify specific influenza virus strains is anticipated in Q4 2010, subject to successful clinical trials and regulatory approval. Enigma will also add additional tests for other areas such as infectious disease management to the ML system test menu in the future.
Financial details of the agreement were not disclosed.
Under the agreement, Tecan will industrialize and deliver commercially manufactured ML instruments for Enigma’s global market supplies for an initial five-year contract and will also manage the ML instrument’s supply chain. The first ML demonstration instruments have been delivered for Enigma’s GlaxoSmithKline delivery commitments for point-of-care molecular diagnostic influenza tests.
The launch of Enigma ML and supply of commercial series systems for its initial use to identify specific influenza virus strains is anticipated in Q4 2010, subject to successful clinical trials and regulatory approval. Enigma will also add additional tests for other areas such as infectious disease management to the ML system test menu in the future.
Financial details of the agreement were not disclosed.